Friday, January 06, 2023 12:40:19 PM
Duracrap will most likely see the same fate as EVERYTHING else in Regen's pipeline of dusty IP.
That is he'll get some of the preclinical trial testing done. He'll release a press release, the stock will get pumped and then we'll hear NOTHING about it OR he'll submit the data to the FDA and get an incomplete response letter back from the FDA, just like he got for HemaX and dCellVax.
Oh, where is Dr. Kesari? Seems he no longer wants to take Koos' phone call
Where is Dyobio and the fast track? The only thing Koos has going is the FAT TRACK!
Where is Brian Koochie Koos and the white paper?
Where is the CSO and CFO?
Where is Lilly?
Where is the funding?
Where is Koos' nose?
ALL UNDENIABLE!!!!
LOL ROFL PIMPL!!!!
FACTS are stubborn things
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM